278 related articles for article (PubMed ID: 18953439)
1. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.
Schneider A; Younis RH; Gutkind JS
Neoplasia; 2008 Nov; 10(11):1295-302. PubMed ID: 18953439
[TBL] [Abstract][Full Text] [Related]
2. Regulation of mTOR and cell growth in response to energy stress by REDD1.
Sofer A; Lei K; Johannessen CM; Ellisen LW
Mol Cell Biol; 2005 Jul; 25(14):5834-45. PubMed ID: 15988001
[TBL] [Abstract][Full Text] [Related]
3. Regulation of hypoxia-inducible factor-1α, regulated in development and DNA damage response-1 and mammalian target of rapamycin in human placental BeWo cells under hypoxia.
Zhou F; Guan LB; Yu P; Wang XD; Hu YY
Placenta; 2016 Sep; 45():24-31. PubMed ID: 27577706
[TBL] [Abstract][Full Text] [Related]
4. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Brugarolas J; Lei K; Hurley RL; Manning BD; Reiling JH; Hafen E; Witters LA; Ellisen LW; Kaelin WG
Genes Dev; 2004 Dec; 18(23):2893-904. PubMed ID: 15545625
[TBL] [Abstract][Full Text] [Related]
5. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced regulation of mTOR signaling by miR-7 targeting REDD1.
Seong M; Lee J; Kang H
J Cell Biochem; 2019 Mar; 120(3):4523-4532. PubMed ID: 30302791
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines.
Chang HW; Lee YS; Nam HY; Han MW; Kim HJ; Moon SY; Jeon H; Park JJ; Carey TE; Chang SE; Kim SW; Kim SY
Cell Signal; 2013 Apr; 25(4):839-47. PubMed ID: 23280187
[TBL] [Abstract][Full Text] [Related]
9. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.
DeYoung MP; Horak P; Sofer A; Sgroi D; Ellisen LW
Genes Dev; 2008 Jan; 22(2):239-51. PubMed ID: 18198340
[TBL] [Abstract][Full Text] [Related]
11. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
[TBL] [Abstract][Full Text] [Related]
12. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
Koo JS; Jung W
Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
[TBL] [Abstract][Full Text] [Related]
13. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase.
Katiyar S; Liu E; Knutzen CA; Lang ES; Lombardo CR; Sankar S; Toth JI; Petroski MD; Ronai Z; Chiang GG
EMBO Rep; 2009 Aug; 10(8):866-72. PubMed ID: 19557001
[TBL] [Abstract][Full Text] [Related]
14. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F
Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236
[TBL] [Abstract][Full Text] [Related]
15. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.
Li X; Lu Y; Lu H; Luo J; Hong Y; Fan Z
Oncotarget; 2015 May; 6(13):11507-18. PubMed ID: 25871473
[TBL] [Abstract][Full Text] [Related]
16. Growth control under stress: mTOR regulation through the REDD1-TSC pathway.
Ellisen LW
Cell Cycle; 2005 Nov; 4(11):1500-02. PubMed ID: 16258273
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
18. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.
Molinolo AA; Hewitt SM; Amornphimoltham P; Keelawat S; Rangdaeng S; Meneses García A; Raimondi AR; Jufe R; Itoiz M; Gao Y; Saranath D; Kaleebi GS; Yoo GH; Leak L; Myers EM; Shintani S; Wong D; Massey HD; Yeudall WA; Lonardo F; Ensley J; Gutkind JS
Clin Cancer Res; 2007 Sep; 13(17):4964-73. PubMed ID: 17785546
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner.
Pinno J; Bongartz H; Klepsch O; Wundrack N; Poli V; Schaper F; Dittrich A
Cell Signal; 2016 Aug; 28(8):907-16. PubMed ID: 27094713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
